
Amer Zeidan/yalemedicine.org
Jun 13, 2025, 06:48
Amer Zeidan Presents ASCERTAIN-V Study on All-Oral Therapy for AML at ASCO25
Amer Zeidan, Associate Professor of Medicine (Hematology) at the Yale University, posted on X:
“What a pleasure to present and usher a new era in AML with total oral therapy through ASCERTAIN-V study at ASCO25 All-Oral Regimen of Decitabine-Cedazuridine plus Venetoclax in Newly Diagnosed AML Ineligible for Intensive Induction Chemo.”
More about ASCO 2025 Symposium on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 13, 2025, 06:48
Jun 13, 2025, 06:27
Jun 13, 2025, 05:44
Jun 13, 2025, 05:35